Crohn’s Disease
Crohn’s Disease Market

Crohn’s Disease (CD) is a type of Inflammatory Bowel Disease (IBD). It causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Inflammation caused by Crohn’s Disease can involve different areas of the digestive tract in different people. However, this type of IBD most commonly affects the small intestine and the start of the colon. Crohn’s Disease can cause patches of inflammation that damage multiple layers of the GI tract wall. Crohn’s Disease can be painful and sometimes may lead to life-threatening complications.

Crohn’s Disease Epidemiological Segmentation

The Epidemiological Segmentation of Crohn’s Disease in the United States from 2018 to 2030 is segmented as:-

  • Total Prevalent Cases of Crohn’s Disease
  • Total Diagnosed Cases of Crohn’s Disease
  • Age-Specific Cases of Crohn’s Disease
  • Severity-specific Cases of Crohn’s Disease
  • Crohn’s Disease Treated Cases 

Crohn’s Disease Epidemiology (2020) 

  • The total number of Crohn’s Disease prevalent cases was 825,165.
  • The total number of Crohn’s Disease severity-specific cases were observed for mild cases to be 236,547, whereas, for moderate cases, it was found to be 354,821 cases.
  • The total number of Crohn's Disease treated cases was 319,339.
  • The total number of Age-specific cases of Crohn’s Disease was observed in the United States:-
  • 351,273 cases - <18–44
  • 170,132 cases - 45–64
  • 68,777 cases -65–84
  • 6,033 cases - ≥85 years 

Crohn’s Disease Market

The therapeutic market of Crohn’s Disease is expected to increase in the US during the study period (2018–2030) with a CAGR of 7.6%.


Crohn’s Disease Market Drivers

  • Increase in Targeted Therapies Penetration Rate and Also Entry of Novel Therapies
  • Advances in Research and Development
  • New Biomarkers for Diagnosis of Crohn’s Disease

Crohn’s Disease Market Barriers

  • Entry of biosimilars in the Crohn’s Disease market
  • Treatment of Fistulizing Patients

Crohn’s Disease Emerging Drugs

The emerging drugs of the Crohn’s Disease market are

  • Jyselica (Fligotinib/GS-6034)
  • Skyrizi (Risankizumab, ABBV-066, BI 655066)
  • Alofisel (Darvadstrocel, Cx601)
  • Mirikizumab (LY3074828)
  • RHB-104
  • Rinvoq (Upadacitinib; ABT494)
  • Zeposia (Ozanimod; RPC1063)
  • Brazikumab (MEDI 2070)
  • Etrasimod (APD334)
  • Tremfya (Guselkumab)
  • Etrolizumab (RG 7413)
  • Ryoncil (Remestemcel-l)
  • SHR 0302
  • JNJ-67864238 (PTG 200)
  • TD-1473 (JNJ 8398)
  • UTTR1147A (RG 7880)
  • Sibofimloc (EB8018/ TAK-018)
  • Tesnatilimab (JNJ-64304500)
  • Deucravacitinib (BMS-986165)
  • BT-11
  • Ritlecitinib (PF-06651600)/ Brepocitinib (PF-06700841)

And many more

Crohn’s Disease Key Players

The key players in the Crohn’s Disease market are

  • Gilead Sciences and Galapagos NV
  • AbbVie and Boehringer Ingelheim
  • Takeda Pharmaceuticals and TiGenix
  • Eli Lilly and Company
  • RedHill Biopharma
  • AbbVie
  • Celgene (Bristol Myers Squibb)
  • AstraZeneca
  • Arena Pharmaceuticals
  • Janssen (Johnson & Johnson)
  • Hoffmann-La Roche; Genentech
  • Mesoblast
  • Reistone Biopharma
  • Protagonist Therapeutics and Janssen (Johnson & Johnson)
  • Theravance Biopharma and Janssen (Johnson & Johnson)
  • Genentech
  • Enterome and Takeda
  • Janssen (Johnson & Johnson)
  • Bristol-Myers Squibb
  • Landos Biopharma
  • Pfizer

And many more